The effect of halogenation on blood–brain barrier permeability of a novel peptide drug☆

The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and remain metabolically stable to produce the desired effect. To improve central nervous system entry of the opioid analgesic [D-Pen2, L-Pen5, Phe6] Enkephalin (DPLPE-Phe), our research group synthesized analogs that had chloro, bromo, fluoro, and iodo halogens on the para positions of the phenylalanine-4 residue. This study reports on investigation of the effect of halogenation on stability, lipophilicity, and in vitro blood-brain barrier permeability of a novel enkephalin analog DPLPE-Phe. The stability of each halogenated DPLPE-Phe analog as well as the amidated and nonamidated parent peptide was tested in plasma and brain. All peptides tested had a half-time disappearance >300 min except for DPLPE-Phe-NH2, which was found to have a half-life of 30 min in plasma. Octanol/saline distribution studies indicated addition of halogens to DPLPE-Phe-OH significantly increased lipophilicity except for p-[F-Phe4]DPLPE-Phe-OH. p-[Cl-Phe4]DPLPE-Phe-OH exhibited the most pronounced increase in lipophilicity. Para-bromo and para-chloro halogen additions significantly enhanced in vitro blood-brain barrier permeability, providing evidence for improved delivery to the central nervous system.

[1]  T. Abbruscato,et al.  Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. , 1999, The Journal of pharmacology and experimental therapeutics.

[2]  M. Goedert,et al.  Endogenous opioid peptides. , 1981, Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg.

[3]  J. Mcdermott,et al.  Human brain leucyl aminopeptidase: Isolation, characterization and specificity against some neuropeptides , 1991, Neuropeptides.

[4]  C. Ferrario,et al.  A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. , 1993, Life sciences.

[5]  K. Audus,et al.  Angiotensin Peptide Regulation of Bovine Brain Microvessel Endothelial Cell Monolayer Permeability , 1991, Journal of Cardiovascular Pharmacology.

[6]  W. Pardridge Peptide drug delivery to the brain , 1991 .

[7]  G. Goldstein,et al.  Brain microvessel endothelial cells in tissue culture: A model for study of blood‐brain barrier permeability , 1983, Annals of neurology.

[8]  I. Romero,et al.  Astrocyte‐endothelial interaction: physiology and pathology , 1992, Neuropathology and applied neurobiology.

[9]  W. Banks,et al.  Peptides and the blood-brain barrier: Lipophilicity as a predictor of permeability , 1985, Brain Research Bulletin.

[10]  Stanley I. Rapoport,et al.  Blood-Brain Barrier in Physiology and Medicine , 1976 .

[11]  V. Hruby,et al.  Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. , 1996, The Journal of pharmacology and experimental therapeutics.

[12]  K. Audus,et al.  Characteristics of Aminopeptidase Activity from Bovine Brain Microvessel Endothelium , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  V. Hruby,et al.  Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. , 1997, The Journal of pharmacology and experimental therapeutics.

[14]  V. Hruby,et al.  Effect of peptidases at the blood brain barrier on the permeability of enkephalin. , 1994, The Journal of pharmacology and experimental therapeutics.

[15]  John Hughes,et al.  Endogenous opioid peptides: multiple agonists and receptors , 1977, Nature.

[16]  V. Hruby,et al.  Brain and Spinal Cord Distribution of Biphalin: Correlation with Opioid Receptor Density and Mechanism of CNS Entry , 1997, Journal of neurochemistry.

[17]  J. Connor,et al.  Receptor‐mediated transcytosis of transferrin across the blood‐brain barrier , 1987, Journal of neuroscience research.

[18]  L. Sherwood Human Physiology : From Cells to Systems , 1989 .

[19]  J. Taylor,et al.  Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. , 1998, The Journal of pharmacology and experimental therapeutics.

[20]  R. Egleton,et al.  Bioavailability and Transport of Peptides and Peptide Drugs into the Brain , 1997, Peptides.

[21]  H. Mitsuya,et al.  Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs , 1992, Antimicrobial Agents and Chemotherapy.

[22]  Thomas J. Raub,et al.  Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. , 1992, Experimental cell research.

[23]  W. Banks,et al.  Saturable transport of peptides across the blood-brain barrier. , 1987, Life sciences.

[24]  V. Hruby,et al.  Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. , 1984, The Journal of pharmacology and experimental therapeutics.

[25]  V A Levin,et al.  Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. , 1980, Journal of medicinal chemistry.

[26]  W. Pardridge,et al.  Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. , 1990, The Journal of pharmacology and experimental therapeutics.

[27]  W. Pardridge,et al.  Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. , 1987, The Journal of biological chemistry.

[28]  T. Davis,et al.  A specific enzyme assay for aminopeptidase M in rat brain. , 1992, Life sciences.

[29]  K. Audus,et al.  Catecholamine‐Metabolizing Enzymes of Bovine Brain Microvessel Endothelial Cell Monolayers , 1986, Journal of neurochemistry.

[30]  W H Oldendorf,et al.  Lipid Solubility and Drug Penetration of the Blood Brain Barrier , 1974, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  T. Terasaki,et al.  Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. , 1989, The Journal of pharmacology and experimental therapeutics.

[32]  V. Hruby,et al.  Cyclic enkephalin analogues with exceptional potency and selectivity for δ-opioid receptors , 1997 .

[33]  T. Davis,et al.  High-performance liquid chromatographic analysis of in vitro central neuropeptide processing. , 1985, Journal of chromatography.

[34]  G. Meisenberg,et al.  Peptides and the blood-brain barrier , 1983 .

[35]  R T Borchardt,et al.  Bovine Brain Microvessel Endothelial Cell Monolayers as a Model System for the Blood‐Brain Barrier a , 1987, Annals of the New York Academy of Sciences.

[36]  N J Abbott,et al.  Electrical resistance across the blood‐brain barrier in anaesthetized rats: a developmental study. , 1990, The Journal of physiology.

[37]  T. Davis 8 – Methods of Measuring Neuropeptides and Their Metabolism , 1991 .

[38]  W. Banks,et al.  Permeability of the blood-brain barrier to peptides: An approach to the development of therapeutically useful analogs , 1992, Peptides.

[39]  R. Egleton,et al.  Transport of the delta-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis1. , 1999, Journal of pharmaceutical sciences.

[40]  H. Mosberg,et al.  Opioid δ-receptor involvement in supraspinal and spinal antinociception in mice , 1987, Brain Research.

[41]  V. Hruby,et al.  Cerebral delta opioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids. , 1984, The Journal of pharmacology and experimental therapeutics.

[42]  Thomas J. Raub,et al.  Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers. , 1990, Journal of cell science.

[43]  Thomas S. Reese,et al.  FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE , 1967, The Journal of cell biology.

[44]  V. Hruby,et al.  Structure-activity relationships of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. , 1997, The Journal of pharmacology and experimental therapeutics.

[45]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[46]  V. Hruby,et al.  [D-Pen2,D-Pen5]enkephalin analogues with increased affinity and selectivity for delta opioid receptors. , 1990, Journal of medicinal chemistry.

[47]  L. Hersh,et al.  Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration. , 1991, The Journal of pharmacology and experimental therapeutics.

[48]  V. Hruby,et al.  Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. , 1993, The Journal of pharmacology and experimental therapeutics.

[49]  H. Kosterlitz,et al.  Types of opioid receptors: relation to antinociception. , 1985, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[50]  W. Pardridge,et al.  Human Blood—Brain Barrier Insulin Receptor , 1985, Journal of neurochemistry.

[51]  T. Tsuruo,et al.  [Functional involvement of P-glycoprotein in blood-brain barrier]. , 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[52]  V. Höllt,et al.  Multiple opioid ligands and receptors in the control of nociception. , 1985, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[53]  S. Williams,et al.  Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. , 1996, The Journal of pharmacology and experimental therapeutics.

[54]  Thomas J. Raub,et al.  Demonstration of Acid Hydrolase Activity in Primary Cultures of Bovine Brain Microvessel Endothelium , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  W. Sadee,et al.  Accelerated communciation: Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence , 1994 .

[56]  S. Nosaka,et al.  Some Characteristics of a Peptidyl Dipeptidase (Kininase II) from Rat CSF: Differential Effects of NaC1 on the Sequential Degradation Steps of Bradykinin , 1990, Journal of neurochemistry.

[57]  I. Romero,et al.  Transporting therapeutics across the blood-brain barrier. , 1996, Molecular medicine today.

[58]  K. Ishikawa,et al.  Further characterization of the in vitro hydrolysis of [Leu]- and [Met]enkephalin in rat plasma: HPLC-ECD measurement of substrate and metabolite concentrations , 1991, Regulatory Peptides.

[59]  W R Martin,et al.  Pharmacology of opioids. , 1983, Pharmacological reviews.

[60]  Thomas J. Raub,et al.  Fluid-phase endocytosis by primary cultures of bovine brain microvessel endothelial cell monolayers. , 1990, Microvascular research.

[61]  G. Scriba,et al.  Metabolism of Catecholamine Esters by Cultured Bovine Brain Microvessel Endothelial Cells , 1989 .

[62]  V. Hruby,et al.  Peptide opioid antagonist separates peripheral and central opioid antitransit effects. , 1987, The Journal of pharmacology and experimental therapeutics.

[63]  L. Hersh Solubilization and characterization of two rat brain membrane-bound aminopeptidases active on Met-enkephalin. , 1981, Biochemistry.